Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

Intraperitoneal delivery of adenoviral gene therapy in vivo is safe and nontoxic. The use of new diluents, already used in peritoneal renal dialysis, will improve drug delivery, reduce therapeutic ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

Based on this, we have developed a new approach to enhance the efficiency of rAAV-mediated gene expression. This approach uses co-infection with a transgene-containing vector and a second vector ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Some of these practices are already necessary as a result of new legislation, such as avoiding superfluous DNA transfer (vector sequences) and replacing selectable marker genes commonly used in ...

vector. “Gene therapy for hearing loss is something physicians and scientists around the world have been working towards for over 20 years,” said Professor John Germiller, the principal ...

To address these limitations of DC as immunotherapeutic agent, we have developed a polymeric nanocomplex incorporating (1) oncolytic adenovirus (oAd ... oAd-mediated cancer gene therapy, ...

serious adverse event in an AAV gene therapy clinical trial (INFINITY, company sponsor Adverum), this time the loss of sight in a patient with diabetic macular edema who was treated with a high dose ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy candidate (KT430) for X-linked myotubular myopathy. Shortly after that ...

Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...